Smith & Nephew stock trades steady as surgical portfolio supports earnings
Smith & Nephew's stock remains stable due to strong performance in its orthopedics and sports medicine franchises. The company reported increased revenue of $5.5 billion in fiscal 2024, up from $5.2 billion in 2023, and maintained a mid-teens trading margin despite investments in innovation …